Abstract
In pediatric patients, Kluyvera spp. has emerged as a cause of disease ranging from soft tissue infections to sepsis with multiorgan failure. Successful treatment options include third-generation cephalosporins, tetracycline, aminoglycosides, and fluoroquinolones, but resistance to first- and second-generation cephalosporins persists. Clinicians should be aware of the spectrum of disease and increasing clinical importance associated with this emerging pathogen.
MeSH terms
-
Adolescent
-
Anti-Bacterial Agents / therapeutic use
-
Child
-
Child, Preschool
-
Drug Resistance, Bacterial
-
Enterobacteriaceae Infections / drug therapy
-
Enterobacteriaceae Infections / microbiology*
-
Female
-
Humans
-
Infant
-
Infant, Newborn
-
Kluyvera / isolation & purification*
-
Male
-
Multiple Organ Failure / etiology
-
Retrospective Studies
-
Sepsis / complications
-
Sepsis / drug therapy
-
Sepsis / microbiology
-
Soft Tissue Infections / drug therapy
-
Soft Tissue Infections / microbiology